Advertisement


Related Videos

Leukemia

Richard M. Stone, MD, on the UK NCRI AML17 Trial

Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract 7, “A Randomized Comparison of Daunorubicin 90 mg/m2 vs 60 mg/m2 in AML Induction: Results From the UK NCRI AML17 Trial in 1206 Patients,” presented by Alan K. Burnett, MD.


Time: 1:29

Lymphoma

Laurie Sehn, MD, on Brentuximab Vedotin in Diffuse Large B-Cell Lymphoma With Undetectable CD30

Laurie Sehn, MD, of the BC Cancer Agency, on abstract 629, “Brentuximab Vedotin Monotherapy in Diffuse Large B-Cell Lymphoma Patients With Undetectable CD30:  Preliminary Results From a Phase II Study.”

Myelodysplastic Syndromes
Leukemia

Alan F. List, MD, on Sotatercept in Lower-Risk Myelodysplastic Syndromes

Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 3251, “An Open-Label, Phase II, Dose-Finding Study of Sotatercept (ACE-011) in Patients With Low or Intermediate-1–Risk Myelodysplastic Syndromes or Nonproliferative Chronic Myelomonocytic Leukemia and Anemia Requiring Transfusion,” presented by Rami S. Komrokji, MD.

Lymphoma

Julie M. Vose, MD, MBA, FASCO, on the AETHERA trial

Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 673, “The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following  Autologous Stem Cell Transplant for Hodgkin Lymphoma,” presented by Craig H. Moskowitz, MD.

Leukemia

Linda J. Burns, MD, on CAR T-Cell Therapy in ALL

2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 380, “T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long-Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL,” presented by Stephan A. Grupp, MD, PhD.


Time: 1:26

Advertisement

Advertisement




Advertisement